Cited by 619Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Open access

Burnett, Alan K., Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert K., Wheatley, Keith·2007·Cancer

DOI 10.1002/cncr.22496

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for older patients who are not considered fit for an intensive chemotherapy approach. METHODS: Between December 1998 and November 2003, as part of National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, who were deemed unfit for intensive chemotherapy were randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily for 10 days) or hydroxyurea with or without all‐trans retinoic acid (ATRA). RESULTS: Low‐dose ara‐C produced a better remission rate (18% vs 1%; odds ratio [OR], 0.15; 95% confidence interval [95% CI], 0.06–0.37; P = .00006) and better overall survival (OR, 0.60; 95% CI, 0.44–0.81; P = .0009), which was accounted for by the achievement of complete remission (CR) (duration of CR: 80 weeks vs 10 weeks for patients with no CR). Patients who had adverse cytogenetics did not benefit. ATRA had no effect. Toxicity scores or supportive care requirements did not differ between the treatment arms. CONCLUSIONS: Older, less fit patients have a poor outcome, and few trials have been conducted in this patient group. Low‐dose ara‐C treatment was superior to best supportive care and hydroxyurea because it had greater success in achieving CR, and it could represent standard care against which new treatments may be compared in this patient group. [See editorial on pages 000–000, this issue.] Cancer 2007 © 2007 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.22496

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
Campos, L., Rouault, J., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J., & Guyotat, D. (1993) · Blood · doi:10.1182/blood.v81.11.3091.3091 · Cited by 783
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Cheson, B. D., Jasperse, D. M., Simon, R. M., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 210
Small doses of ARA‐C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
Housset, M., Daniel, M., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 189
Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 179
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid
Andreeff, M., Jiang, S., Zhang, X., Konopleva, M. Y., Estrov, Z. E., Snell, V., Xie, Z., Okcu, M., Sanchez‐Williams, G., Dong, J., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401573 · Cited by 153
Sexual functioning morbidity among cancer survivors. Current status and future research directions
Andersen, B. L. (1985) · Cancer · doi:10.1002/1097-0142(19850415)55:8 · Cited by 147

Flagged first, then by citations

Show all 26 references

1 of the 26 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–600 of 619

Consensus in acute myeloid leukemia in Mexico
Arana-Luna, L. L., Alvarado‐Ibarra, M., Silva-Michel, L. G., Morales-Maravilla, A., González-Rubio, M. D. C., Chávez-Aguilar, L. A., Tena-Iturralde, M. F., Mojica-Balceras, L., Zapata-Canto, N., Galindo-Delgado, P., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000598 · Cited by 2
Treatment of acute myeloid leukaemia in older patients – scope of intensive therapy? – A retrospective analysis
Mayer, K. T., Serries, M., Hahn‐Ast, C., Bisht, S., Brossart, P., & Feldmann, G. (2023) · Hematology · doi:10.1080/16078454.2023.2212536 · Cited by 2
Is less always more? Emerging treatment concepts in geriatric hemato-oncology
Neuendorff, N. R., Reinhardt, H. C., & Christofyllakis, K. (2023) · Ageing and Cancer Research & Treatment · doi:10.37155/2972-4759-2023-01-01-2 · Cited by 4
Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia
Savona, M. R., & Wei, A. H. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00400 · Cited by 2
A Remarkable Remission: Treating HMA Refractory Transforming MDS with Single-Agent Low-Dose Cytarabine Leading to an Ongoing Six-Year OS
Palmer, D. A., & Jones, L. (2020) · Case Reports in Medicine · doi:10.1155/2020/1540370 · Cited by 2
Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future
Craddock, C. (2020) · British Journal of Haematology · doi:10.1111/bjh.17146 · Cited by 2
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy
Wang, L., & Lin, N. (2021) · Medicine · doi:10.1097/md.0000000000024703 · Cited by 2
Myeloid Malignancies
Zeidner, J. F., Roy, D. B., Perl, A. E., & Gojo, I. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch29 · Cited by 2
Akute myeloische Leukämie
Röllig, C., Thiede, C., & Ehninger, G. (2017) · Der Onkologe · doi:10.1007/s00761-017-0199-5 · Cited by 1
Treatment of Newly Diagnosed AML in Unfit Patients
Vey, N. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_10 · Cited by 1
Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia
Zayac, A. S., & Reagan, J. L. (2021) · Hemato · doi:10.3390/hemato2030033 · Cited by 1
Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry
Karakuş, V., Pınar, İ. E., İltar, U., Yenihayat, E. M., Polat, M. G., Çelik, S., Malkan, Ü. Y., Seval, G. C., Doğan, A., Akdeniz, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207367 · Cited by 1
Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in acute myeloid leukemia
Namgoong, S., Ham, S., Courcoubetis, G., Tsang, J., Yi, H., Lim, S., & Koo, J. (2026) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-026-00260-y · Cited by 1
Aktuelle Behandlungsmöglichkeiten akuter myeloischer Leukämien
Heuser, M., Schlenk, R. F., & Ganser, A. (2011) · Der Internist · doi:10.1007/s00108-011-2929-x · Cited by 1
RETRACTED ARTICLE: 5-Azacitidine for treating acute myelogenous leukemia
Fakih, R. O. E., Champlin, R. E., & Oran, B. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1089168 · Cited by 1
Retracted
Treating older patients with AML
Amadori, S. (2012) · Leukemia Supplements · doi:10.1038/leusup.2012.11 · Cited by 1
Treatment of elderly and very old patients with AML
Koller, E. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0249-5 · Cited by 1
Hematological Improvement is a Favorable Response to Azacitidine in Patients with Acute Myeloid Leukemias and Myelodysplastic Syndromes
Kostroma, I. I., Грицаев, С. В., Karyagina, E. V., Низамутдинова, А. С., Степановна, М. И., & Абдулкадыров, К. М. (2015) · Clinical oncohematology · doi:10.21320/2500-2139-2015-8-4-413-419 · Cited by 1
Cytogenetic and Molecular Aberrations as Predictive Biomarkers in Acute Myeloid Leukemia
Heeg, S., & Waller, C. F. (2012) · Springer eBooks · doi:10.1007/978-1-4419-9755-5_6 · Cited by 1
Myelodysplastic Syndromes
Steensma, D. P., & Stone, R. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00099-0 · Cited by 1
Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemia
Du, Y., Li, C., Chen, Y., Xie, F., & Yan, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02612-1 · Cited by 1
ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia
Vyas, P., Salek, S., Vives, S., Récher, C., Döhner, H., Venditti, A., Derrien, H., Chatin, S., Bigne, A.-M. D. L., Pelouchová, J., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2567838 · Cited by 1
Self-citation
In search of a solution
Galhena, R. (2008) · Containerisation international · Cited by 1
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)
Atalay, F., & Ateşoğlu, E. B. (2015) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-015-0509-2 · Cited by 1
Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials
Mahdi, A. J., Mahdi, E. J. G., & Knapper, S. (2015) · Clinical Investigation · doi:10.4155/cli.14.112 · Cited by 1
Management considerations in older patients with AML: a 2014 perspective.
Medeiros, B. C. (2014) · PubMed · Cited by 1
Coexistence of T-cell lymphoblastic lymphoma and acute myeloid leukemia mimicking acute lymphocytic leukemia
Li, W., Liu, K., Zhou, F., Fu, Z., & Yin, J. (2018) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_6_18 · Cited by 1
An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia
Ip, K., Bedair, K., & Tauro, S. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106348 · Cited by 1
A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes
Zhu, H. J., Yang, B., Liu, J., Wang, B., Wu, Y., Zheng, Z., & Ling, Y. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211009334 · Cited by 1
Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle
Phillips, D. F., & Zeidner, J. F. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1950689 · Cited by 1
Acute Myeloid Leukemia in Older Adults
Loh, K. P., Pardee, T. S., & Klepin, H. D. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_42 · Cited by 1
Is Traditional Low-Dose Chemotherapy (Cytarabine/Melphalan) Still an Option for the Treatment of Myelodysplastic Syndromes?
Whittle, A. M., & Bowen, D. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.023 · Cited by 1
Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms
Stone, R. M., & Schiffer, C. A. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm115 · Cited by 1
Iodine spiking phenomenon in pressurized water reactor coolants
Chubb, W., Piplica, E. J., & Lutz, R. (1977) · Transactions of the American Nuclear Society · Cited by 1
TP53 mutations in myelodysplastic syndromes with deletion of 5q
Saft, L. (2013) · Figshare
Management of acute myeloid leukemia
Burnett, A. K. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781926.002
Self-citation
The characterisation of telomere dynamics in Myelodysplastic syndromes
Williams, J. (2014) · ORCA Online Research @Cardiff (Cardiff University)
Highlights from the 2008 Meeting of the American Society of Hematology San Francisco, CA; December 6–9, 2008
Shrader, M., Xu, B.-E., Cortes, J. E., & Faderl, S. H. (2009) · Clinical Leukemia · doi:10.3816/clk.2009.n.001
Are new agents really making a difference in MDS?
Stone, R. M. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.06.004
Acute Myeloid Leukemia in Older Patients: Special Problems and Possible Solutions
Venugopal, P., Batus, M., & Gregory, S. A. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.031
An inexpensive way to treat elderly patients with high-risk MDS or AML
Kuendgen, A. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.03.026
The changing face of acute myeloid leukemia therapeutics in the elderly population
Daver, N. G., & Cortes, J. E. (2015) · South Asian Journal of Cancer · doi:10.4103/2278-330x.149900
David Galton – the thesis years
Dyer, M. J. S. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701706188
Treating Elderly Patients with Acute Myeloid Leukemia: Implications of Prognostic Modeling for the Development of New Therapies
Jurcic, J. G. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.019
Liquid Tumors in the Elderly
Mato, A. R., Feldman, T. A., Richter, J. R., Siegel, D. S. D., & Goy, A. H. (2012) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.12.002
Risikoadaptierte Therapie der akuten myeloischen Leukämie
Fiegl, M., & Hiddemann, W. (2012) · Der Internist · doi:10.1007/s00108-011-2986-1 · Cited by 1
Treating the Elderly Patient with Acute Myelogenous Leukemia
Payandeh, M., & Aeinfar, M. (2012) · Journal of Hematological Malignancies · doi:10.5430/jhm.v2n4p22
Is Chemotherapy Really the Best Option in Older Adults with Acute Myeloid Leukemia?
Ferrara, F., Angelillo, P., Carbone, A., & Riccardi, C. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.44
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors
Hackanson, B. W., Becker, H., Berg, T., Binder, M., Dierks, C., Duque‐Afonso, J., Lairmore, M. D., Schäfer, H. S., Schnitzler, M., Zeiser, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6859
Low dose cytarabine monotherapy for acute myeloid leukaemia
Bauer, K. H., Hutzschenreuter, F., Monsef, I., Skoetz, N., Kreuzer, K., & Engert, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009480.pub2
Long-term Complete Remission in a 71-year-old Patient with AML-M7 after Low-dose Cytarabine Induction and Intermediate-dose Cytarabine Consolidation Treatment
Kwon, J. H., Kim, J. W., Park, J. H., Koh, Y., Kim, J. H., Bang, S. M., Song, J., & Lee, J.-S. (2009) · The Korean Journal of Hematology · doi:10.5045/kjh.2009.44.4.244
Acute Myeloid Leukemias: 10-Year Therapy Experience
Baranova, O. Y., Antipova, A. S., Zakharov, O. D., Falaleeva, N. A., Kaletin, G. I., Shirin, A. D., Arakelyan, G. R., Tupitsyn, N. N., Frenkel', M. A., Александровна, К. Н., et al. (2015) · Clinical oncohematology · doi:10.21320/2500-2139-2015-8-3-287-301
Expert Insights into the Contemporary Management of Older Adults with Acute Myeloid Leukemia
Ravandi, F., Erba, H. P., & Pollyea, D. A. (2013) · Cancer Control · doi:10.1177/107327481302004s02
Acute myeloid leukaemia - therapy - past, present and future
Faduola, P., Hakim, A. J., Mansnérus, J., Imai, A., & Neill, R. O. (2013) · Translational Biomedicine
Impact des comorbidités sur le pronostic des patients âgés de plus de 75 ans traités par azacitidine pour myélodysplasie de haut risque ou leucémie aiguë myéloblastique
Sabatier, P., Clinique, M. S., & Bréchemier, D. (2014)
Akute Leukämien
Gökbuget, N., Brunnberg, U., & Serve, H. L. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50255-7
A phase I trial of bexarotene, a retinoid X receptor agonist, in non-M3 acute myeloid leukemia
Tsai, D. E., Luger, S. M., Kemner, A., Andreadis, C., Loren, A. W., Porter, D., Stadtmauer, E., Swider, C. R., Goradia, A., & Carroll, M. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7061
Less Intensive Therapy For Older Aml Patients
Clarke, W. T. (2013)
Sapacitabine in acute myelogenous leukemia
McCloskey, J. K., Koprivnikar, J. L., & Faderl, S. H. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1100992
Prise en charge thérapeutique des leucémies aiguës myéloïdes
Prébet, T., Etienne, A., & Vey, N. (2012) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(12)51281-1
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults:
Tallman, M. S., Löwenberg, B., Bloomfield, C. D., Grimwade, D. J., Larson, R. A., Naoe, T., Niederwieser, D. W., Ossenkoppele, G. J., Sanz, M. Á., Dohner, J., et al. (2010)
Self-citation
Improving outcomes for elderly patients with AML
Mehta, A. I., & Sampson, J. H. (2012)
Acute Myelogenous Leukemia in the Elderly.
Oliai, C. H., & Schiller, G. J. (2015)
Therapeutic management of acute myeloid leukemia
Fiegl, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-26772-2_5
Akute myeloische Leukämie beim alten und geriatrischen Patienten
Krug, U. O., Lengfelder, E., & Sauer, T. (2018) · Springer eBooks · doi:10.1007/978-3-662-48727-3_16
Early Parenteral Supplementation with Glutamine Dipeptide for Acute Myeloid Leukaemia Patients Receiving High Dose Chemotherapy
Selim, D. H., El-Fatah, N. K. A., Darwish, O. A., Deghady, A. A. M., & Elghandour, A. (2015) · Journal of High Institute of Public Health · doi:10.21608/jhiph.2015.20238
Acute Myeloid Leukemia in Older Adults
Loh, K. P., Pardee, T. S., & Klepin, H. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-44870-1_42-1
VI. Chemotherapies for Leukemia in Elderly
Yamauchi, T. (2018) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.107.1309
Was ist gesichert in der Therapie der akuten myeloischen Leukämie?
Thol, F. R. (2019) · Der Internist · doi:10.1007/s00108-019-00696-w
FLT3-ITD Negative Refractory/Relapsed or Geratic AML Patients Responded Well to Salvage Treatment with Low Dose Cytarabine and Sorafenib
Jianhui, X., Qian-Qian, Y., Zhong, Y., He, Y., Du, J., Minhong, L., Yuxian, H., Li, Y., & Bingyi, W. (2019) · International Journal of Clinical and Experimental Medical Sciences · doi:10.11648/j.ijcems.20190506.11
[Study of the effects and mechanism of all-trans retinoic acid on leukemic cell line U937 cells with NPM1 mutation].
Qiu, S., Wan, Y. L., Jia, Y., Rao, Q., Wang, M., & Wang, J. X. (2017) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2017.10.008
Prolonged Survival of a 79-Year Old Man with Acute Myeloid Leukemia M2, Normal Karyotype, NPM1 and FLT3-ITD Mutations, WBC 33.7 × 109/L, and Involving only Granulocyte-Macrophage Line on 53 Cycles of Low-Dose Cytarabine
Lemež, P., Dignum, H., Ganczakowski, M., Chiecchio, L., Ayto, R., Baker, K. S., Singh, S., Cranfield, T., Matthias, G., James, C., et al. (2019) · Annals of Hematology & Oncology · doi:10.26420/annhematoloncol.2019.1276
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Rodríguez‐Medina, C., Martínez‐Cuadrón, D., Cano, I., Gil, C., Tormo, M., Martínez‐Sánchez, M. P., Bernal, T., Serrano, J., Benavente, C., Herrera‐Puente, P., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106352
Akute myeloische Leukämie
Lippl, S., & Spiekermann, K. (2015) · Info Onkologie · doi:10.1007/s15004-015-0710-3
Hämatologische und onkologische Erkrankungen
Schrezenmeier, H., & Hiller, E. (2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50012-1
Hämatologische und onkologische Erkrankungen
Gstatter, S., & Berthold, H. K. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-45381-6.00039-6
Dilemmák egy új kezeléssel remisszióba hozott AML-beteg esete kapcsán: a kezelés intenciójának változása
Kellner, Á., Rajnics, P., Kollár, B., Karádi, É., Ercsei, I., Pavlovics, A., Káposztás, Z., Ternyik, L., Kajtár, B., Kereskai, L., et al. (2020) · Hematológia–Transzfuziológia · doi:10.1556/2068.2020.53.4.5
Efficacy of platelet transfusions
Kerkhoffs, J. (2012) · Leiden Repository (Leiden University)
Tratamento de leucemia e mieloide aguda no idoso
Meira, R., Camelo, S., Alexandra, M., & Silva, S. M. (2014)
Targeting the Mitochondrial Peptidase Neurolysin in Acute Myeloid Leukemia
Mirali, S. (2020) · TSpace (University of Toronto)
Less Intensive 1 (LI1) Trial: A Randomized Phase II/III Clinical Trial in Approximately 1000 Elderly Patients With Acute Myeloid Leukaemia (AML) Deemed Not Suitable for Intensive ChemotherapyPreprint
Thomas, I., Dennis, M., Upton, L., Ariti, C. A., Russell, N. H., Hills, R. K., Copland, M., & Burnett, A. K. (2021) · Research Square · doi:10.21203/rs.3.rs-434566/v1
Self-citation
Management of acute myeloid leukemia in older adults
Rao, A. V., & Moore, J. O. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511763182.017
Faculty Opinions recommendation of Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Teachey, D. T. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735366643.793581827
Current Awareness in Hematological Oncology
(2007) · Hematological Oncology · doi:10.1002/hon.798
Myelodysplastic Syndromes
Steensma, D. P., & Stone, R. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00096-7
Management of myelodysplastic syndromes and acute myeloid leukaemias in the elderly
Bréchemier, D., Garric, M., & Nadaï, T. D. (2022) · Pathy's Principles and Practice of Geriatric Medicine · doi:10.1002/9781119484288.ch27
Traitement des syndromes myélodysplasiques
Fenaux, P., Adès, L., & Itzykson, R. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_44
Treating acute myeloid leukaemia in patients over 60 years of age in the era of targeted therapy
Hisemová, M., & Ráčil, Z. (2022) · Onkologie · doi:10.36290/xon.2022.005
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-2
Akute myeloische Leukämie beim alten und geriatrischen Patienten
Krug, U. O., Lengfelder, E., & Sauer, T. (2017) · Springer eBooks · doi:10.1007/978-3-662-49083-9_16-1
Low dose cytarabine monotherapy for acute myeloid leukaemia
Bauer, K. H., Hutzschenreuter, F., Monsef, I., Skoetz, N., Kreuzer, K., & Engert, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009480
Retracted
Acute Leukemia
Itzykson, R., & Boissel, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-18257-5_28
Akute myeloische Leukämie
Neubauer, A., & Röllig, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_463-1
Erstlinientherapie nicht-intensiv therapierbarer AML-Patient*innen
Ghandili, S., Modemann, F., Bokemeyer, C., & Fiedler, W. (2022) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-022-9122-3
Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms
Stone, R. M., Schiffer, C. A., & DeAngelo, D. J. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm115.pub2
Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
Usikova, E. V., Kaplanov, K. D., Vorobyev, V. I., Lobanova, T. I., Ul'yanova, M. A., Kisilichina, D. G., Kobzev, Y. N., Шихбабаева, Д. И., Vinogradova, O., & Ptushkin, V. V. (2022) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2022.6.clin.5
Molecular Signatures in Acute Myeloid Leukemia: From Diagnosis to Targeted Therapy and Drug Repositioning
Kelesoglu, N., Karademir-Yilmaz, B., & Arğa, K. Y. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_84
Practical aspects of the use of ventoclax in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia in patients ineligible for intensive chemotherapy
Szczepaniak, A., Gil, L., Giebel, S., Helbig, G., Wróbel, T., Zaucha, J. M., Budziszewska, B. K., & Wierzbowska, A. (2023) · Hematology in Clinical Practice · doi:10.5603/hcp.a2022.0018
Data from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2023) · doi:10.1158/1078-0432.c.6530669
Data from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2023) · doi:10.1158/1078-0432.c.6530669.v1

Authors: Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K.
Affiliations: Cardiff University (GB)
Heartlands Hospital (GB)
Derriford Hospital (GB)
University College Hospital (GB)
Belfast City Hospital (GB)
Cancer Research UK Clinical Trials Unit (GB)
Corresponding author: Burnett, Alan K.
ORCID: Burnett, Alan K.
Goldstone, Anthony H.
McMullin, Mary F.
Hills, Robert K.
Wheatley, Keith
Venue: Cancer
Publisher: Wiley
Published: 2007-02-21
Volume: 109
Issue: 6
Pages: 1114-1124
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.22496
OpenAlex: W2068556430
Cited by: 619
References: 26
Citations by year: 2026: 5 · 2025: 14 · 2024: 13 · 2023: 23 · 2022: 28 · 2021: 43 · 2020: 45 · 2019: 40 · 2018: 29 · 2017: 37 · 2016: 36 · 2015: 54 · 2014: 48 · 2013: 42 · 2012: 36
FWCI: 18.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Research Portal (Queen's University Belfast) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: acute myeloid leukemia, high-risk myelodysplastic syndrome, low-dose cytarabine, hydroxyurea, all-trans retinoic acid, elderly patients, complete remission, overall survival, adverse cytogenetics, best supportive care
MeSH terms: Acute Disease, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Female, Humans, Hydroxyurea, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Risk, Survival, Tretinoin, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks